insomnia news from FierceBiotech

Shares of Vanda Pharmaceuticals shot up this morning after researchers announced that its late-stage trial for treating chronic insomnia hit its primary endpoint. The goal was to demonstrate the Read more...

Facing a delay of clinical trials for its lead therapy, Neurogen slashed 45 more jobs and announced plans to focus its development programs. The developer also raised $30.6 million in a private Read more...

> Here's statistical confirmation of the gloom-and-doom facing Big Pharma. Worldwide sales growth will Read more...

Evotec has given a thumb's up on its Phase II data on its insomnia drug EVT 201. In the trial of 149 patients over the age of 65 researchers found that the lower dose extended sleep time by nine Read more...

The market for insomnia drugs in the U.S. is growing at a whopping 29 percent per year, hitting $4.6 billion in 2006 and attracting the attention of a wide range of drug developers. More than a Read more...

San Diego-based Arena Pharmaceuticals has delivered positive mid-stage data on APD125, an experimental therapy for chronic insomnia. The therapy is being developed for people who have a hard time Read more...

Germany's Evotec is boosting its pipeline to five compounds with the acquisition of Renovis for $152 million in an all-stock transaction. An insomnia drug is slated to begin a human clinical trial by Read more...

> GlaxoSmithKline has signed on to commercialize Sepracor's insomnia drug Lunesta, agreeing to pay $20 million up front and up to $155 million in total for milestones and licensing fees. Glaxo Read more...

Actelion says its experimental sleep therapy has performed well in a clinical trial, raising the prospects of a new class of sleep drugs that inhibit orexin, a chemical in the brain believed to keep Read more...

> Belgium's Elbion NV has acquired some late-stage drug candidates from DrugAbuse Sciences. Two of the therapies are sustained-release forms of currently approved drug. Naltrexone Depot, an antagonist that blocks receptors in the brain and is used in the treatment of opiate and alcohol abuse, is expected to head into Phase III this year. Buprenorphine Depot, a sustained release buprenorphine indicated for the treatment of opiate addiction, is also included in the portfolio. No …

Read more...